EUVIMEDEUVIMED entdecken
Crossref

New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations

Walid E Elgammal iD, Hazem Elkady iD, Hazem A Mahdy, Bshra A Alsfouk iD, Dalal Z Husein, Fatma G Amin, Abdelrahman A Abuelkhir, Eslam B Elkaeed, Ahmed M Metwaly iD, Ibrahim H Eissa iD

Archiv der Pharmazie · 2025-09 · 358 (9)

DOI: 10.1002/ardp.70097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 28.09.2025. Verfasst von Walid E Elgammal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Thiadiazoles, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: This study was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R142), Princess Nourah bint Abdulrahman U….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study reports the design, synthesis, and biological evaluation of a novel series of 1,3,4‐thiadiazole‐based derivatives as dual B‐Raf and VEGFR‐2 kinase inhibitors with potential anticancer activity. Among the synthesized compounds, 7b emerged as the most potent candidate, exhibiting strong cytotoxicity against the MDA‐MB‐231 and MCF‐7 breast cancer cell lines (IC₅₀ = 9.66 and 15.83 µM, respectively), with minimal toxicity toward normal WI‐38 and WISH cells, reflected by favorable selectivity indices. Compound 7b , featuring a unique structural assembly of a 2,3‐dihydro‐1,3,4‐thiadiazole core, a para ‐methoxyphenyl group, and a sulfonamide‐linked methylpiperidine moiety, exhibited superior dual‐inhibitory activity. It showed IC₅₀ values of 0.75 µM for B‐Raf and 58.13 nM for VEGFR‐2. Flow cytometry and gene expression analysis revealed that 7b induces G1‐phase cell‐cycle arrest and promotes apoptosis through the upregulation of BAX, caspases‐8/9, and downregulation of Bcl‐2. Compound 7b also inhibited cell migration in wound‐healing assays. Structure–activity relationship (SAR) analysis indicated that para ‐substituted electron‐donating groups enhanced cytotoxic potency. Molecular docking and molecular dynamics simulations confirmed the stable binding of 7b to the kinase active sites, supported by favorable Glide scores (–25.47 kcal/mol for VEGFR‐2 and –31.64 kcal/mol) and MM‐GBSA (molecular mechanics with generalized Born and surface area solvation) binding energies. Density functional theory (DFT) calculations further validated the compound's electronic stability and reactivity. These integrated findings suggest that compound 7b is a promising lead for further development as a selective dual kinase inhibitor for breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesAntineoplastic AgentsDrug DesignBreast NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafHumansStructure-Activity RelationshipFemaleMolecular StructureDrug Screening Assays, AntitumorApoptosisCell ProliferationMolecular Docking SimulationDose-Response Relationship, DrugMCF-7 CellsCell Line, Tumor

Stichwörter der Autor:innen

1,3,4‐thiadiazoleB‐RafMD simulationsVEGFR‐2breast cancermolecular docking

Substanzen

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesAntineoplastic AgentsProtein Kinase InhibitorsKDR protein, humanProto-Oncogene Proteins B-raf1,3,4-thiadiazole

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.
  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
  • Physics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
  • Department of Pharmaceutical Organic Chemistry, College of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Walid E Elgammal, Hazem Elkady, Bshra A Alsfouk, Ahmed M Metwaly, Ibrahim H Eissa

Förderung

  • This study was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R142), Princess Nourah bint Abdulrahman U…

Zitieren

APA

Elgammal, W. E., Elkady, H., Mahdy, H. A., Alsfouk, B. A., Husein, D. Z., Amin, F. G., Abuelkhir, A. A., Elkaeed, E. B., Metwaly, A. M., & Eissa, I. H. (2025). New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations. Archiv der Pharmazie, 358(9). https://doi.org/10.1002/ardp.70097

Vancouver

Elgammal WE, Elkady H, Mahdy HA, Alsfouk BA, Husein DZ, Amin FG, et al. New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations. Archiv der Pharmazie. 2025;358(9). doi:10.1002/ardp.70097

BibTeX
@article{Elgammal2025,
  author = {Elgammal, Walid E and Elkady, Hazem and Mahdy, Hazem A and Alsfouk, Bshra A and Husein, Dalal Z and Amin, Fatma G and Abuelkhir, Abdelrahman A and Elkaeed, Eslam B and Metwaly, Ahmed M and Eissa, Ibrahim H},
  title = {New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {9},
  doi = {10.1002/ardp.70097}
}
Kostenlos starten →